JP7542876B2 - 神経突起成長及びシナプス形成活性を持つ新規プロリルｆｋ５０６誘導体及びその用途 - Google Patents

神経突起成長及びシナプス形成活性を持つ新規プロリルｆｋ５０６誘導体及びその用途 Download PDF

Info

Publication number
JP7542876B2
JP7542876B2 JP2022578690A JP2022578690A JP7542876B2 JP 7542876 B2 JP7542876 B2 JP 7542876B2 JP 2022578690 A JP2022578690 A JP 2022578690A JP 2022578690 A JP2022578690 A JP 2022578690A JP 7542876 B2 JP7542876 B2 JP 7542876B2
Authority
JP
Japan
Prior art keywords
deoxo
prolyl
disease
dihydro
demethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022578690A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531456A (ja
Inventor
ユン，ヨジュン
ソン，ミョンジョン
チョン，ジンア
チョン，ウンジ
キム，サンウ
イ，ホンジュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molgenbio Co Ltd
Original Assignee
Molgenbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molgenbio Co Ltd filed Critical Molgenbio Co Ltd
Publication of JP2023531456A publication Critical patent/JP2023531456A/ja
Application granted granted Critical
Publication of JP7542876B2 publication Critical patent/JP7542876B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0053—Oxidoreductases (1.) acting on a heme group of donors (1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022578690A 2020-06-19 2021-06-18 神経突起成長及びシナプス形成活性を持つ新規プロリルｆｋ５０６誘導体及びその用途 Active JP7542876B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200075285 2020-06-19
KR10-2020-0075285 2020-06-19
PCT/KR2021/007681 WO2021256894A1 (fr) 2020-06-19 2021-06-18 Nouveaux dérivés de prolylfk506 ayant des activités de croissance des neurites et de formation de synapses et leurs utilisations

Publications (2)

Publication Number Publication Date
JP2023531456A JP2023531456A (ja) 2023-07-24
JP7542876B2 true JP7542876B2 (ja) 2024-09-02

Family

ID=79178403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578690A Active JP7542876B2 (ja) 2020-06-19 2021-06-18 神経突起成長及びシナプス形成活性を持つ新規プロリルｆｋ５０６誘導体及びその用途

Country Status (6)

Country Link
US (1) US20230137836A1 (fr)
EP (1) EP4169923B1 (fr)
JP (1) JP7542876B2 (fr)
KR (1) KR102388366B1 (fr)
CN (1) CN115916787B (fr)
WO (1) WO2021256894A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518387A (ja) 2014-06-30 2017-07-06 イントロン・バイオテクノロジー・カンパニー・リミテッド Ｆｋ５０６誘導体を含有するクリプトコッカス属カビ及びカンジダ属カビによる真菌感染を治療するための薬剤学的組成物及びその用途 ｛ｐｈａｒｍａｃｅｕｔｉｃａｌ ｃｏｍｐｏｓｉｔｉｏｎ ｃｏｎｔａｉｎｉｎｇ ｆｋ５０６ ｄｅｒｉｖａｔｉｖｅ ｆｏｒ ｔｒｅａｔｉｎｇ ｆｕｎｇａｌ ｉｎｆｅｃｔｉｏｎ ｃａｕｓｅｄ ｂｙ ｇｅｎｕｓ ｃｒｙｐｔｏｃｏｃｃｕｓ ａｎｄ ｇｅｎｕｓ ｃａｎｄｉｄａ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920700212A (ko) * 1989-06-14 1992-02-19 쟝 크라머·한스 루돌프 하우스 헤테로원자-함유 트리사이클릭 화합물
CA2051872A1 (fr) * 1990-09-24 1992-03-25 Kevin M. Byrne Procede de biosynthese dirigee de la prolyl-immunomycine
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
CN102023433B (zh) * 2009-09-18 2012-02-29 北京京东方光电科技有限公司 Tft-lcd阵列基板及其制造方法
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
KR20160067079A (ko) * 2016-06-02 2016-06-13 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
KR102134782B1 (ko) * 2018-12-11 2020-07-17 주식회사 인트론바이오테크놀로지 신규 화합물 및 이를 포함하는 신경계 질환 치료용 약학적 조성물
US20230094227A1 (en) * 2020-12-24 2023-03-30 Seoul National University R&Db Foundation Novel fk506 derivative and composition comprising same for promoting hair growth

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518387A (ja) 2014-06-30 2017-07-06 イントロン・バイオテクノロジー・カンパニー・リミテッド Ｆｋ５０６誘導体を含有するクリプトコッカス属カビ及びカンジダ属カビによる真菌感染を治療するための薬剤学的組成物及びその用途 ｛ｐｈａｒｍａｃｅｕｔｉｃａｌ ｃｏｍｐｏｓｉｔｉｏｎ ｃｏｎｔａｉｎｉｎｇ ｆｋ５０６ ｄｅｒｉｖａｔｉｖｅ ｆｏｒ ｔｒｅａｔｉｎｇ ｆｕｎｇａｌ ｉｎｆｅｃｔｉｏｎ ｃａｕｓｅｄ ｂｙ ｇｅｎｕｓ ｃｒｙｐｔｏｃｏｃｃｕｓ ａｎｄ ｇｅｎｕｓ ｃａｎｄｉｄａ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝

Also Published As

Publication number Publication date
KR102388366B1 (ko) 2022-04-21
US20230137836A1 (en) 2023-05-04
EP4169923A4 (fr) 2024-03-13
JP2023531456A (ja) 2023-07-24
EP4169923C0 (fr) 2026-02-25
EP4169923A1 (fr) 2023-04-26
CN115916787B (zh) 2025-04-04
EP4169923B1 (fr) 2026-02-25
WO2021256894A1 (fr) 2021-12-23
CN115916787A (zh) 2023-04-04
KR20210157357A (ko) 2021-12-28

Similar Documents

Publication Publication Date Title
US10576060B2 (en) FK506 derivative maintaining nerve regeneration activity without immunosuppressive activity, and use thereof
CN111171020A (zh) 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
JP7542876B2 (ja) 神経突起成長及びシナプス形成活性を持つ新規プロリルｆｋ５０６誘導体及びその用途
KR102134782B1 (ko) 신규 화합물 및 이를 포함하는 신경계 질환 치료용 약학적 조성물
KR102342772B1 (ko) 매크로라이드계 유도체 화합물, 이의 생산 방법 및 용도
CN111278985B (zh) 具有针对鸟分枝杆菌复合体感染疾病治疗活性的新型化合物及其制造方法
CN115151557A (zh) 含哌嗪酸的环肽化合物、其生产方法及其用途
WO2007023778A1 (fr) Nouveau médicament concomitant anticancéreux
EP3901157B1 (fr) Composé et composition le comprenant pour stimuler la pousse des cheveux
KR102681872B1 (ko) 신규한 스피로-매크로라이드 화합물, 이의 생산 방법 및 용도
KR101721665B1 (ko) 아미드계 유도체 화합물, 이의 생산 방법 및 용도
US20230094227A1 (en) Novel fk506 derivative and composition comprising same for promoting hair growth
US11820762B2 (en) Compounds as potential therapeutic agents targeting various neurodegenerative diseases
KR102690860B1 (ko) 남극 진균 균주 Pleosporales sp. SF-7343 유래 대사화합물을 포함하는 염증질환 예방 또는 치료용 조성물
US12011497B2 (en) Compounds, compositions containing same, and use thereof for promoting hair growth
JP3683003B2 (ja) 抗腫瘍性物質エポラクタエン
KR20250006724A (ko) 신규한 디테르펜 화합물 및 유도체, 이의 용도, 및 이의 생산 방법
CN117551034A (zh) 天赐霉素类似物及其制备方法和应用
KR20250129852A (ko) 신규한 옥사졸로마이신 화합물, 이의 생산 방법 및 용도
KR20220005412A (ko) 삼중환 다이락톤 화합물, 이의 생산 방법, 및 용도
JP4833461B2 (ja) 新規血管新生阻害剤
JP2004269456A (ja) 新規発酵生産物
JPH0381225A (ja) 抗真菌剤
JP2016179953A (ja) 新規サガミラクタム物質およびその製造法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240604

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240814

R150 Certificate of patent or registration of utility model

Ref document number: 7542876

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150